Abatacept (ABA) is the first and only one of biological disease-modifying anti-rheumatic drugs (bDMARDs) for rheumatoid arthritis (RA) that inhibits T lymphocyte activation by binding to CD80/86, thereby modulating its interaction with CD28. This evidence concerns the gene CD28 and rheumatoid arthritis.